Laboratory monitoring of antiretroviral therapy for HIV infection: Cost-effectiveness and budget impact of current and novel strategies

Clinical Infectious Diseases

Volumn 62, Issue 11, 2016, Pages 1454-1462

  Ouattara, Eric N ^a,b,c   Robine, Marion ^d   Eholié, Serge P ^b   Maclean, Rachel L ^d   Moh, Raoul ^b   Losina, Elena ^d,e   Gabillard, Delphine ^a   Paltiel, A David ^f   Danel, Christine ^a,b   Walensky, Rochelle P ^d,e   Anglaret, Xavier ^a,b   Freedberg, Kenneth A ^d,e,g,h  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b University Hospital of Treichville   (Côte d’Ivoire)

^c University Hospital Centre ^*  (France)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f YALE UNIVERSITY   (United States)

^g BOSTON UNIVERSITY   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

ART; cost effectiveness; HIV; laboratory monitoring; viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS LOPINAVIR PLUS RITONAVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; BUDGET IMPACT; CD4 LYMPHOCYTE COUNT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COTE D'IVOIRE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT CARE; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DRUG MONITORING; ECONOMICS; HIV INFECTIONS; MIDDLE AGED; THEORETICAL MODEL;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; VIRAL LOAD;

EID: 84971508899     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw117     Document Type: Article

References (41)

1. World Health Organization. Actual and projected numbers of people receiving antiretroviral therapy in low-And middle-income countries by WHO region and in high-income countries across WHO regions, 2003-2015. Available at: http://www. who.int/hiv/data/art-2003-2015.png.ua=1. Accessed 11 November 2015.
2. UNAIDS. How AIDS changed everything. Available at: http://www.unaids.org/sites/default/files/media-Asset/MDG6Report-en.pdf. Accessed 11 November 2015.
3. Petersen ML, Tran L, Geng EH, et al. Delayed switch of antiretroviral therapy after virologic failure associated with elevated mortality among HIV-infected adults in Africa. AIDS 2014; 28:2097-107.
4. Schooley RT. Viral load testing in resource-limited settings. Clin Infect Dis 2007; 44:139-40.
5. World Health Organization. Guidelines on when to start antiretroviral therapy and pre-exposure prophylaxis for HIV. Available at: http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565-eng.pdf.ua=1. Accessed 11 November 2015.
6. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
7. Temprano ANRS Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 373:808-22.
8. Insight START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795-807.
9. Anglaret X, Scott CA, Walensky RP, et al. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A modelbased analysis. Antivir Ther 2013; 18:45-55.
10. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-31.
11. Ouattara EN, Ross EL, Yazdanpanah Y, et al. Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a modelbased analysis in Côte dIvoire. J Acquir Immune Defic Syndr 2014; 66:294-302.
12. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276:1253-8.
13. Anglaret X, Chne G, Attia A, et al. Early chemoprophylaxis with trimethoprimsulphamethoxazole for HIV-1-infected adults in Abidjan, Côte dIvoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353:1463-8.
14. Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost-effectiveness of co-Trimoxazole prophylaxis in patients with HIV/AIDS in Côte dIvoire: a trialbased analysis. AIDS 2005; 19:1299-308.
15. The World Bank. GDP per capita (current US$). Available at: http://data. worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed 10 February 2014.
16. Anglaret X, Minga A, Gabillard D, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Côte dIvoire. Clin Infect Dis 2012; 54:714-23.
17. Losina E, Yazdanpanah Y, Deuffic-Burban S, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte dIvoire. Antivir Ther 2007; 12:543-51.
18. Walensky RP, Ross EL, Kumarasamy N, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med 2013; 369:1715-25.
19. Messou E, ChaixML, Gabillard D, et al. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte dIvoire. J Acquir Immune Defic Syndr 2011; 56:356-64.
20. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:500-6.
21. Clinton Health Access Initiative (CHAI). Antiretroviral (ARV) ceiling price list. Available at: http://45.55.138.94/content/uploads/2015/05/CHAI-ARV-Ceiling-Price-2014-Final-English.pdf. Accessed 11 November 2015.
22. UNITAID. HIV/AIDS Diagnostic Technology Landscape, 2nd Edition. Available at: http://www.unitaid.eu/images/marketdynamics/publications/UNITAIDHIV-Diagnostics-Landscape-2nd-edition.pdf. Accessed 11 November 2015.
23. Ross E, Tanser F, Pei P, et al. The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials. HIV Clin Trials 2014; 15:185-98.
24. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in West Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-9.
25. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Available at: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf. Accessed 11 November 2015.
26. Rapport annuel des indicateurs VIH du secteur santé en Côte dIvoire, 2012: direction de linformation, de la planification et de levaluation (DIPE) (not published). Accessed 11 November 2015.
27. UNAIDS. AidsInfo: Côte dIvoire data. Available at: http://www.unaids.org/en/dataanalysis/datatools/aidsinfo/. Accessed 11 November 2015.
28. UNAIDS. Report on the global AIDS epidemic. Available at: http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf. Accessed 11 November 2015.
29. Tagar E, Sundaram M, Condliffe K, et al. Multi-country analysis of treatment costs for HIV/AIDS (MATCH): facility-level ART unit cost analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia. PLoS One 2014; 9:e108304.
30. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and metaanalysis. AIDS 2009; 23:1397-404.
31. Estill J, Egger M, Johnson LF, et al. Monitoring of antiretroviral therapy and mortality in HIV programmes in Malawi, South Africa and Zambia: mathematical modelling study. PLoS One 2013; 8:e57611.
32. Kimmel AD, Weinstein MC, Anglaret X, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010; 54:258-68.
33. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371:1443-51.
34. Braithwaite RS, Nucifora KA, Yiannoutsos CT, et al. Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? J Int AIDS Soc 2011; 14:38.
35. Keebler D, Revill P, Braithwaite S, et al. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Lancet Glob Health 2014; 2:e35-43.
36. Braithwaite SR, Nucifora KA, Toohey C, et al. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? AIDS 2014; 28(suppl 1):S73-83.
37. Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan APhillips A, Shroufi A, et al. Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature 2015; 528: S68-76.
38. UNAIDS. Landmark HIV diagnostic access program will save $150m and help achieve new global goals on HIV. Available at: http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2014/september/20140925prviralload. Accessed 10 February 2016.
39. Médecins Sans Frontières. Untangling the web of antiretroviral price reductions. 15th Edition. Available at: http://d2pd3b5abq75bb.cloudfront.net/2013/09/11/10/25/44/896/MSF-Access-UTW-16th-Edition-2013.pdf. Accessed May 20 2015.
40. De Beaudrap P, Thiam M, Diouf A, et al. Risk of virological failure and drug resistance during first-And second-line antiretroviral therapy in a 10-year cohort in Senegal: results from the ANRS 1215 cohort. J Acquir Immune Defic Syndr 2013; 62:381-7.
41. Jobanputra K, Parker LA, Azih C, et al. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS One 2015; 10: e0116144.